Organization: Enzon Pharmaceuticals Inc

Inex co-development deal with Enzon terminated

A development and commercialization agreement between Inex Pharmaceuticals Corp, Vancouver, and Enzon Pharmaceuticals Inc, Bridgewater NJ, has been terminated following the decision of the FDA to issue a “not approvable” letter for Inex’s leading anti-cancer drug, Marqibo. Inex received a final $5-million payment from Enzon and is seeking new investment. The collaboration with Enzon lasted…

Inex strikes lucrative collaboration agreement

Burnaby BC-based Inex Pharmaceuticals Corp has entered a strategic partnership with Enzon Pharmaceuticals Inc, Bridgewater NJ, for the development and commercialization of its Onco TCS oncology drug. Inex will receive US$12 million up front and an additional US$20 million when it receives FDA approval for its rolling new drug application, expected this spring. Further milestone…